This review aimed to summarize the currently available information on angiotensin receptor neprilysin inhibitor (sacubitril/valsartan, ARNI), a novel therapeutic approach for heart failure with reduced ejection failure (HFrEF). Drug development, pharmacokinetics, molecular and hemodynamic effects and clinical effects of ARNI were discussed